Geode Capital Management
CHRS icon

Geode Capital Management’s Coherus Oncology CHRS Stock Holding History

Geode Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
3,685,567
+563,989
+18% +$921K ﹤0.01% 2900
2026
Q1 		$5.28M Buy
3,121,578
+376,332
+14% +$668K ﹤0.01% 2707
2025
Q4 		$3.9M Buy
2,745,246
+4,020
+0.1% +$5.86K ﹤0.01% 2902
2025
Q3 		$4.5M Buy
2,741,226
+64,750
+2% +$72K ﹤0.01% 2846
2025
Q2 		$1.96M Buy
2,676,476
+20,976
+0.8% +$18.1K ﹤0.01% 3152
2025
Q1 		$2.14M Buy
2,655,500
+55,861
+2% +$64.3K ﹤0.01% 3008
2024
Q4 		$3.59M Buy
2,599,639
+34,494
+1% +$38.7K ﹤0.01% 2905
2024
Q3 		$2.67M Buy
2,565,145
+182,914
+8% +$251K ﹤0.01% 3037
2024
Q2 		$4.12M Buy
2,382,231
+178,537
+8% +$359K ﹤0.01% 2838
2024
Q1 		$5.27M Buy
2,203,694
+122,093
+6% +$300K ﹤0.01% 2671
2023
Q4 		$6.93M Buy
2,081,601
+136,634
+7% +$366K ﹤0.01% 2536
2023
Q3 		$7.28M Buy
1,944,967
+524,359
+37% +$2.42M ﹤0.01% 2447
2023
Q2 		$6.07M Buy
1,420,608
+112,238
+9% +$662K ﹤0.01% 2582
2023
Q1 		$8.95M Buy
1,308,370
+47,950
+4% +$372K ﹤0.01% 2323
2022
Q4 		$9.98M Buy
1,260,420
+31,211
+3% +$240K ﹤0.01% 2268
2022
Q3 		$11.8M Buy
1,229,209
+32,357
+3% +$327K ﹤0.01% 2113
2022
Q2 		$8.66M Buy
1,196,852
+28,796
+2% +$250K ﹤0.01% 2354
2022
Q1 		$15.1M Sell
1,168,056
-26,704
-2% -$340K ﹤0.01% 2074
2021
Q4 		$19.1M Sell
1,194,760
-3,024
-0.3% -$52.9K ﹤0.01% 1990
2021
Q3 		$19.2M Buy
1,197,784
+14,216
+1% +$208K ﹤0.01% 1983
2021
Q2 		$16.4M Buy
1,183,568
+84,257
+8% +$1.19M ﹤0.01% 2108
2021
Q1 		$16.1M Buy
1,099,311
+111,841
+11% +$1.9M ﹤0.01% 2014
2020
Q4 		$17.2M Buy
987,470
+29,410
+3% +$524K ﹤0.01% 1815
2020
Q3 		$17.6M Buy
958,060
+3,101
+0.3% +$57.7K ﹤0.01% 1618
2020
Q2 		$17.1M Sell
954,959
-14,023
-1% -$237K ﹤0.01% 1612
2020
Q1 		$15.7M Buy
968,982
+74,836
+8% +$1.38M ﹤0.01% 1461
2019
Q4 		$16.1M Buy
894,146
+37,577
+4% +$693K ﹤0.01% 1703
2019
Q3 		$17.4M Buy
856,569
+65,606
+8% +$1.31M ﹤0.01% 1574
2019
Q2 		$17.5M Buy
790,963
+93,978
+13% +$1.63M ﹤0.01% 1572
2019
Q1 		$9.51M Buy
696,985
+66,510
+11% +$887K ﹤0.01% 1929
2018
Q4 		$5.71M Sell
630,475
-5,339
-0.8% -$61.8K ﹤0.01% 2140
2018
Q3 		$10.5M Buy
635,814
+128,389
+25% +$2.28M ﹤0.01% 1888
2018
Q2 		$7.1M Buy
507,425
+71,097
+16% +$1.02M ﹤0.01% 2111
2018
Q1 		$4.82M Buy
436,328
+47,315
+12% +$518K ﹤0.01% 2258
2017
Q4 		$3.42M Buy
389,013
+9,621
+3% +$103K ﹤0.01% 2448
2017
Q3 		$5.06M Buy
379,392
+56,266
+17% +$744K ﹤0.01% 2199
2017
Q2 		$4.64M Buy
323,126
+50,377
+18% +$969K ﹤0.01% 2193
2017
Q1 		$5.77M Buy
272,749
+34,139
+14% +$840K ﹤0.01% 2005
2016
Q4 		$6.72M Buy
238,610
+22,449
+10% +$628K ﹤0.01% 1861
2016
Q3 		$5.79M Buy
216,161
+10,696
+5% +$292K ﹤0.01% 1876
2016
Q2 		$3.47M Buy
205,465
+103,752
+102% +$1.95M ﹤0.01% 2134
2016
Q1 		$2.16K Buy
101,713
+8,935
+10% +$146K ﹤0.01% 2403
2015
Q4 		$2.13M Buy
92,778
+3,291
+4% +$84.7K ﹤0.01% 2434
2015
Q3 		$1.79M Buy
89,487
+2,871
+3% +$87.4K ﹤0.01% 2515
2015
Q2 		$2.5M Buy
86,616
+25,023
+41% +$633K ﹤0.01% 2352
2015
Q1 		$1.88M Buy
61,593
+24,466
+66% +$632K ﹤0.01% 2479
2014
Q4 		$605K Buy
+37,127
New +$524K ﹤0.01% 3100

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Geode Capital Management's CHRS Position: Q2 2026 in Review

Geode Capital Management increased its Coherus Oncology (CHRS) stake by 18% in Q2 2026, buying an estimated $921K and bringing the position to 3,685,567 shares worth $5.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Geode Capital Management first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $19.2M in Q3 2021. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Geode Capital Management held 3,685,567 shares of Coherus Oncology worth $5.16M as of Q2 2026.
  • Geode Capital Management bought 563,989 Coherus Oncology shares in Q2 2026, an estimated $921K.
  • Coherus Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2900 holding.
  • Geode Capital Management first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Coherus Oncology position peaked at $19.2M in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.